J B Chemicals & Pharmaceuticals Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xt8nywm4xmiuh2hwxvat22zd.pdf

Key Takeaways


Domestic Business: Chronic Strength, Acute Softness

Nikhil Chopra: "Unfortunately for us and fortunately for the betterment of the mankind and humidity that people did not suffer from the GI infections. That is why you don't see the traction."

CDMO: The Second Growth Engine


Margins & Cost Structure

Nikhil Chopra: "Fortunately, Rahul for us, I think in the first half of the year we have been on the higher side of the guidance that we have been giving. So, you can take that as a new guidance from us."

International Business & South Africa Reset

Nikhil Chopra: "So South Africa, we have taken a haircut of around... you should assume that it should be close to around Rs.120 crore."

Capital Allocation: M&A and “Buy Versus Build”

Kunal Khanna: "I think the key takeaway for all of us is if you compare the acquisitions which we have made versus some of the other acquisitions which have happened, one will clearly understand that we have been judicious about our capital allocation strategy, right. So, we just don't believe in acquiring top line and paying a higher multiple."

Brand & Portfolio Updates


Guidance & Commitments

CommitmentSpecificsTimeline
Domestic growth12–14% growth, 200–300 bps above IPM (8–12%)Ongoing
Operating EBITDA marginHigher side of 25–27% range; H1 outcome of 28.5% treated as new guidanceOngoing
CDMO revenue target~$100 million (from ~$50 million last year)~3 years (mid-to-long term)
India + CDMO sales mix75–80% of overall sales~3 years (mid-to-long term)
International growth (ex-SA reset)Double-digit (~12%)Next year
CDMO new launches2–3 new launches; gestation 24–30 monthsSecond half of next year
ProductivityINR7 lakh; inch up thereafter with 10–12% growthThis year and next
South Africa base resetINR120 crore annualized haircut absorbed; base resetComplete
Lozenges capacityDouble capacity on newly acquired adjacent land2–3 years
Field forceNo addition to 2,200 repsNear future

Key Metrics

MetricQ2 FY24
Revenue₹882 cr, up ~9% YoY
Gross marginUp 350 bps YoY
Operating EBITDA margin28.5%, up from 25% in Q2 FY23
Operating EBITDA margin (H1 FY24)27.8%, up from 24.6% in H1 FY23
Operating EBITDA (H1 FY24)₹494 cr, up from ₹392 cr in H1 FY23
Operating cash flow (H1 FY24)₹421 cr, up from ₹279 cr in H1 FY23
Domestic revenue₹481 cr, up 11% YoY
International business revenue₹401 cr
CDMO revenue₹115 cr
Gross debt₹427 cr as of Sep 30, 2023, down from ₹548 cr as of Mar 31, 2023
Net debt₹18 cr as of Sep 30, 2023, down from ₹266 cr as of Mar 31, 2023
CAPEX (H1 FY24)₹93 cr; full-year estimate ₹145 cr
IPM rank growth (MAT Sep 2023)~18%, fastest growing in Top 25 vs IPM growth of 10%
Chronic segment growth (MAT Sep 2023)18% YoY, fastest in Top 25 vs IPM chronic growth of 12%
Domestic chronic mix52–53%
Acute portfolio growth (Q2 FY24)~6%; Rantac, Metrogyl franchise grew 5–7%
Cilacar franchise revenueNearing ₹600 cr
Rantac franchise revenue₹400 cr
Metrogyl franchise revenueCrossed ₹300 cr
Sporlac brand rank336, close to entering top 300
South Africa revenue haircut (annualized)~₹120 cr; ~₹30 cr in Q2
Medical reps~2,200, meeting ~2.5 lakh doctors
Rep productivity (expected FY24)~₹7 lakh
Lozenges manufacturing throughput17–18 cr lozenges/month; packaging 12–13 cr
Azmarda market share16–18%
Azmarda market volume16–18 lakh units/month, up from ~10 lakh pre-LOE
Razel run rate~₹6 cr, up from ~₹4 cr at acquisition
Pediatrics business~₹150 cr annually
Domestic + CDMO combined share~65–67% currently; target 75–80% in ~3 years
CDMO business target$100 million in ~3 years
International business growth target (next year)~12% (double digit)
EBITDA margin guidance25–27%, trending toward upper side